Bevacizumab Slows Ovarian Cancer Progression
By Kristina Fiore, Staff Writer, MedPage TodayPublished: February 25, 2010
Maintenance therapy with bevacizumab (Avastin) following combination therapy with the drug and chemotherapy improved progression-free survival with previously untreated, advanced ovarian cancer, drugmaker Genentech announced.
The company said all women in the phase III trial had surgery to remove their tumors, then were randomized to one of three groups:
- Placebo plus carboplatin and paclitaxel chemotherapy, followed by placebo alone for maintenance therapy
- Bevacizumab plus carboplatin and paclitaxel, followed by placebo alone for maintenance therapy
- Bevacizumab plus carboplatin and paclitaxel, followed by maintenance therapy with bevacizumab
Women who had maintenance therapy with bevacizumab had longer progression-free survival than the other groups, Genentech said, although the company did not release specific data.
Full data are expected to be reported at the American Society of Clinical Oncology meeting in Chicago in June.
Those who received bevacizumab and chemotherapy but no maintenance therapy did not have improved progression-free survival, the company said.
With regard to safety, the company noted similar serious adverse events previously seen with the drug, including fatal neutropenic infection and gastrointestinal perforation.
The phase III Gynecologic Oncology Group (GOG) 0218 study is an international, multicenter, randomized, double-blind, placebo-controlled trial of 1,873 women with newly diagnosed and previously untreated advanced epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.
It is sponsored by the National Cancer Institute and Genentech, which is owned by Roche.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου